

CONFERENCE PROGRAM

Monday, January 8

- 6:00 p.m.–8:00 p.m.** **WELCOME REMARKS AND OPENING KEYNOTE SESSION**
Legends 1-4
Fred Hirsch, CEO, IASLC
- 6:10 p.m.–6:40 p.m. **Checkpoint blockade: “The good, bad, and the ugly”**
Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY
- 6:40 p.m.–7:10 p.m. **The role of aneuploidy during tumorigenesis**
Teresa Davoli, Harvard Medical School, Boston, MA
- 7:10 p.m.–7:40 p.m. **Functional lung cancer genomics through in vivo genome editing**
Monte M. Winslow, Stanford University School of Medicine, Stanford, CA
- 7:40 p.m.–8:00 p.m. **Keynote discussion**
- 8:00 p.m.–10:00 p.m.** **OPENING RECEPTION**
The Edge

Tuesday, January 9

- 7:00 a.m.–8:00 a.m.** **CONTINENTAL BREAKFAST**
The Edge
- 8:00 a.m.–10:00 a.m.** **PLENARY SESSION 1: EARLY STEPS IN LUNG ONCOGENESIS**
Legends 1-4
- 8:00 a.m.–8:25 a.m. **Elucidating lung stem cells and the initiation of lung cancer at single-cell resolution**
Mark A. Krasnow, Stanford University, Stanford, CA
- 8:25 a.m.–8:50 a.m. **Early steps in lung oncogenesis**
Samuel Janes, University College London, London, United Kingdom
- 8:50 a.m.–9:15 a.m. **Molecular mechanisms of lung cancer development: Between metabolic reprogramming and genomic instability in the field of cancerization**
Pierre P. Massion, Vanderbilt University Medical Center, Nashville, TN
- 9:15 a.m.–9:40 a.m. **Influence of cancer initiation on tumor progression in SCLC**
Julien Sage, Stanford University School of Medicine, Stanford, CA
- 9:40 a.m.–9:55 a.m. **Modeling Rb loss and pathway reactivation in lung adenocarcinoma***
David M. Feldser, University of Pennsylvania, Philadelphia, PA
- 10:00 a.m.–10:30 a.m.** **BREAK**
Abbey Road
- 10:30 a.m.–12:25 p.m.** **PLENARY SESSION 2: EARLY DETECTION**
Legends 1-4
- 10:30 a.m.–10:55 a.m. **Individualized risk-based lung cancer screening: The way forward**
Christine D. Berg, National Cancer Institute, Bethesda, MD
- 10:55 a.m.–11:20 a.m. **Inflammation and immunity in pulmonary premalignancy**
Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA

**Short talk from proffered abstract*

CONFERENCE PROGRAM

11:20 a.m.–11:45 a.m.	Title to be announced Avrum E. Spira, Boston University School of Medicine, Boston, MA
11:45 a.m.–12:10 p.m.	Gene networks, airway smoke injury, and cancer risk Bruce A.J. Ponder, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
12:10 p.m.–12:25 p.m.	Diagnostic and prognostic utility of urinary creatine riboside for early-stage non-small cell lung cancer* Takahiro Oike, National Cancer Institute, Bethesda, MD
12:25 p.m. – 12:35 p.m.	POSTER SESSION A HIGHLIGHTS Legends 1-4 (not CME accredited)
(A01)	Stem cell signals in the initiation and progression of non-small cell lung cancer Alison G. Barber, University of California San Diego School of Medicine, San Diego, CA
(A02)	Oncogenic drivers of lung cancer induce production of CCL5 and recruitment of regulatory T cells Elizabeth Franks, British Columbia Cancer Research Centre, Vancouver, BC, Canada
(A03)	Reversion of EMT sensitizes KRAS mutant cancers to MEK inhibition David H. Peng, The University of Texas MD Anderson Cancer Center, Houston, TX
(A04)	Altered expression of lncRNAs overlapping pseudogene loci as an alternative mechanism of cancer gene regulation Greg L. Stewart, British Columbia Cancer Research Centre, Vancouver, BC, Canada
12:40 p.m.–2:00 p.m.	POSTER SESSION A AND LUNCH Legends 5-6 and Encore
2:30 p.m.–3:45 p.m.	PLENARY SESSION 3: LIQUID BIOPSIES Legends 1-4
2:30 p.m.–2:55 p.m.	Early detection of molecular residual disease in localized lung cancer via circulating tumor DNA profiling Maximilian Diehn, Stanford University, Stanford, CA
2:55 p.m.–3:20 p.m.	Circulating tumor DNA in early-stage NSCLC: A lung TRACERx study Christopher Abbosh, University College London Cancer Institute, London, United Kingdom
3:20 p.m.–3:45 p.m.	ctDNA assessment of resistance and heterogeneity in EGFR mutant lung cancers Zofia Piotrowska, Partners Cancer Care/MGH Cancer Center, Boston, MA
3:45 p.m.–4:00 p.m.	BREAK Abbey Road
4:00 p.m.–6:15 p.m.	PLENARY SESSION 4: HETEROGENEITY AND EVOLUTION Legends 1-4
4:00 p.m.–4:25 p.m.	Liquid biopsies and lung cancer evolution Trevor G. Bivona, University of California San Francisco, San Francisco, CA
4:25 p.m.–4:50 p.m.	Tracking Lung Cancer Evolution through therapy (TRACERx): Immune evasion, progression, and adaptation Charles Swanton, The Francis Crick Institute and University College London Cancer Institute, London, United Kingdom

*Short talk from proffered abstract

CONFERENCE PROGRAM

- 4:50 p.m.–5:15 p.m. **Evolution of acquired resistance in EGFR-mutant NSCLC**
Aaron N. Hata, Massachusetts General Hospital, Charlestown, MA
- 5:15 p.m.–5:40 p.m. **Cell-of-origin footprints in lung cancer genomes and transcriptomes**
Marcin Imielinski, Weill Cornell Medical College, New York, NY
- 5:40 p.m.–5:55 p.m. **Dissecting the playbook of cancer: Genomic analysis of 100,000 human tumors reveals elaborate patterns of activation of the RTK-RAS-MAPK pathway***
Gerard Manning, Genentech, South San Francisco, CA
- 5:55 p.m.–6:10 p.m. **Decoding tumor microenvironment to enhance NSCLC targeted therapy***
Haichuan Hu, MGH Cancer Center/Harvard Medical School, Charlestown, MA

Wednesday, January 10

- 7:00 a.m.–8:00 a.m. CONTINENTAL BREAKFAST**
The Edge
- 8:00 a.m.–10:00 a.m. PLENARY SESSION 5: IMMUNOTHERAPY: BIOMARKERS AND CHECKPOINT BLOCKADE**
Legends 1-4
- 8:00 a.m.–8:25 a.m. **Immunotherapy: Biomarkers and checkpoint blockade in NSCLC**
David P. Carbone, The Ohio State University Comprehensive Cancer Center, Columbus, OH
- 8:25 a.m.–8:50 a.m. **Mechanisms of acquired resistance to immune checkpoint inhibitors in lung cancer**
Katerina A. Politi, Yale University Cancer Center, New Haven, CT
- 8:50 a.m.–9:15 a.m. **Immunotherapy for thoracic malignancies beyond NSCLC**
Solange Peters, Centre Cordonné d'Oncologie-CHUV, Lausanne, Switzerland
- 9:15 a.m.–9:30 a.m. **Safety and activity of the IL-15/sIL-15R α complex ALT-803 in combination with the anti-PD1 mAb nivolumab in metastatic non-small cell lung cancer***
John Wrangle, Medical University of South Carolina, Charleston, SC
- 9:30 a.m.–9:45 a.m. **Investigating ectopic lymphoid aggregates in a genetically engineered mouse model of lung adenocarcinoma***
Kelli Connolly, Yale University, New Haven, CT
- 9:45 a.m.–10:00 a.m. **Role of the microbiota in inflammation and lung cancer***
Ana I. Robles, National Cancer Institute, Bethesda, MD
- 10:00 a.m.–10:30 a.m. BREAK**
Abbey Road
- 10:30 a.m.–11:20 a.m. PLENARY SESSION 6: VACCINES, CELLULAR THERAPY, NEOANTIGEN TARGETING**
Legends 1-4
- 10:30 a.m.–10:55 a.m. **Allele-specific HLA loss and immune escape in lung cancer evolution**
Rachel Rosenthal, University College London, London, United Kingdom
- 10:55 a.m.–11:20 a.m. **Are tumors predictable? Inherited immune variation constrains tumor evolution**
Hannah K. Carter, University of California San Diego, San Diego, CA
- 11:30 a.m.–12:00 p.m. SPECIAL LECTURE**
Legends 1-4
- Developing precision medicine-based new lung cancer therapeutics**
John D. Minna, UT Southwestern Medical Center, Dallas, TX

*Short talk from proffered abstract

CONFERENCE PROGRAM

12:00 p.m.–1:30 p.m.	LUNCH ON OWN
1:30 p.m.–3:40 p.m.	PLENARY SESSION 7: SMALL CELL LUNG CANCER Legends 1-4
1:30 p.m.–1:55 p.m.	Mechanisms of chemoresistance in SCLC Charles M. Rudin, Memorial Sloan Kettering Cancer Center, New York, NY
1:55 p.m.–2:20 p.m.	MYC drives molecular and therapeutically distinct subtype of SCLC Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
2:20 p.m.–2:45 p.m.	The genomic landscape of SCLC and other neuroendocrine lung tumors Julie George, University of Cologne, Cologne, Germany
2:45 p.m.–3:10 p.m.	Circulating Tumor Cells: A liquid biopsy for SCLC with multiple applications Caroline Dive, Cancer Research UK Manchester Institute, Manchester, United Kingdom
3:10 p.m.–3:25 p.m.	Functional characterization and evolutionary reconstruction of small cell lung cancer transformation of EGFR-mutant lung adenocarcinomas* June-Koo Lee, Harvard Medical School, Boston, MA
3:25 p.m.–3:40 p.m.	Alterations in cell junctions and neuroendocrine differentiation are key early steps in Crebbp/Ep300 mutation-driven SCLC development* Kwon-Sik Park, University of Virginia, Charlottesville, VA
3:40 p.m.–4:00 p.m.	BREAK Abbey Road
4:00 p.m.–5:30 p.m.	PLENARY SESSION 8: IMAGING, RADIATION ONCOLOGY, RADIOMICS Legends 1-4
4:00 p.m.–4:25 p.m.	ImmunoPET imaging of DLL3 in small cell lung cancer John T. Poirier, Memorial Sloan Kettering Cancer Center, New York, NY
4:25 p.m.–4:50 p.m.	Radiation therapy in lung cancer: Recent trends and future directions Daniel R. Gomez, The University of Texas MD Anderson Cancer Center, Houston, TX
4:50 p.m.–5:15 p.m.	Multiscale modeling of lung cancer Olivier Gevaert, Stanford University, Stanford, CA
5:15 p.m.–5:30 p.m.	Multimodality imaging of human lung squamous cell carcinoma reveals unique metabolic dependencies that are effectively targeted with metabolic-based therapies* David B. Shackelford, David Geffen School of Medicine at UCLA, Los Angeles, CA
5:30 p.m.–5:40 p.m.	POSTER SESSION B HIGHLIGHTS Legends 1-4 <i>(not CME accredited)</i>
(B01)	BLU-667: A highly selective RET inhibitor to target RET-driven NSCLC Erica K. Evans, Blueprint Medicines, Cambridge, MA
(B02)	Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention Koji Fukuda, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
(B03)	Suppression of lung adenocarcinoma growth and metastasis by stromal Hedgehog pathway activation James Kim, UT Southwestern Medical Center, Dallas, TX
5:40 p.m.–7:00 p.m.	POSTER SESSION B AND RECEPTION Legends 5-6 and Encore

*Short talk from proffered abstract

Thursday, January 11

7:00 a.m.–8:00 a.m.	CONTINENTAL BREAKFAST The Edge
8:00 a.m.–10:00 a.m.	PLENARY SESSION 9: TUMOR MICROENVIRONMENT Legends 1-4
8:00 a.m.–8:25 a.m.	Comprehensive enumeration of immune cells in the tumor microenvironment using multiplexed ion beam imaging Michael Angelo, Stanford University School of Medicine, Stanford, CA
8:25 a.m.–8:50 a.m.	Targeting cellular heterogeneity in lung adenocarcinoma Tuomas Tammela, Memorial Sloan Kettering Cancer Center, New York, NY
8:50 a.m.–9:15 a.m.	Immune contexture evolution during lung cancer carcinogenesis and its potential clinical implications Jianjun Zhang, The University of Texas MD Anderson Cancer Center, Houston, TX
9:15 a.m.–9:40 a.m.	Regulatory T cells, polymorphisms, and response to checkpoint blockade: From mechanisms to potential biomarkers Sergio Quezada, University College London Cancer Institute, London, United Kingdom
9:40 a.m.–9:55 a.m.	Hyperspectral imaging tools capture the spatial organization of cell subsets within the tumor microenvironment* Katey S.S. Enfield, British Columbia Cancer Research Centre, Vancouver, BC, Canada
10:00 a.m.–10:15 a.m.	BREAK Abbey Road
10:15 a.m.–12:00 p.m.	PLENARY SESSION 10: TARGETED THERAPIES AND ONCOGENIC SIGNALING Legends 1-4
10:15 a.m.–10:40 a.m.	Title to be announced Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, NY
10:40 a.m.–10:55 a.m.	A combined protein-protein interaction and genetic interaction map defines new and critical Kras effectors in non-small cell lung cancer* Peter K. Jackson, Stanford University School of Medicine, Stanford, CA
10:55 a.m.–11:20 a.m.	Progress and unanswered questions in EGFR mutation-positive lung cancer Lecia Sequist, Massachusetts General Hospital, Boston, MA
11:20 a.m.–11:35 a.m.	MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer* Shigeki Nanjo, University of California San Francisco, San Francisco, CA
11:35 a.m.–12:00 p.m.	The art in the science of ALK-positive lung cancer management Tony S.K. Mok, Chinese University of Hong Kong, Shatin, Hong Kong

**Short talk from proffered abstract*